Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABT-122 + methotrexate
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
ABT-122 + methotrexate is a combination therapy comprising **ABT-122**, a bispecific dual variable domain immunoglobulin (DVD-Ig™) biologic, and **methotrexate**, a conventional disease-modifying antirheumatic drug (DMARD). ABT-122 is designed to bind and neutralize both tumor necrosis factor (TNF) and interleukin-17A (IL-17A), two key cytokines involved in driving inflammation in autoimmune diseases. Methotrexate, the backbone DMARD, inhibits dihydrofolate reductase, thereby reducing inflammation and immune activity. This combination has been investigated primarily for patients with **rheumatoid arthritis (RA)** and **psoriatic arthritis (PsA)** who have had an inadequate response to methotrexate alone[1][2][3][4][6][8].
- Brand names
- ABBV-257ABBV257ABBV 257
- Other names
- Dual-variable domain immunoglobulin 1 + methotrexateDVD-Ig 1 + methotrexate
02
Targets
IL-17A (Interleukin-17A)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on ABT-122 + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABT-122 + methotrexate.